Author

Ander Arbelaiz

Observed names: A Arbelaiz, A. Arbelaiz, Ander Arbelaiz Cossio, Arbelaiz Cossio, Ander

Institutions: Inserm, University of the Basque Country, Sorbonne Université, Biogipuzkoa Health Research Institute, Centre de Recherche Saint-Antoine, Donostiako Unibertsitate Ospitalea

Observed institutions: Universidad de Cantabria, Inserm, University of the Basque Country, Sichuan University, Sorbonne Université, West China Hospital of Sichuan University, Marqués de Valdecilla University Hospital, Biogipuzkoa Health Research Institute, Hôpital Saint-Antoine, Instituto de Investigación Marqués de Valdecilla, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Centre de Recherche Saint-Antoine, Donostiako Unibertsitate Ospitalea

OpenAlex ID: A5080153357

Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

2017 · Ander Arbelaiz, Mikel Azkargorta, et al. · Hepatology · 289

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

2023 · Ainhoa Lapitz, Mikel Azkargorta, et al. · Journal of Hepatology · 185

PDF

Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

2018 · Jesus M. Banales, Mercedes Iñarrairaegui, et al. · Hepatology · 179

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

2018 · Maria J Perugorria, Aitor Esparza-Baquer, et al. · Gut · 143

PDF

MicroRNA‐506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

2017 · Oihane Erice, Patricia Munoz‐Garrido, et al. · Hepatology · 95

PDF

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

2020 · Ainhoa Lapitz, Ander Arbelaiz, et al. · Cells · 94

PDF

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

2017 · O. Erice, I. Labiano, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 80

Cold-Atmospheric Plasma Induces Tumor Cell Death in Preclinical In Vivo and In Vitro Models of Human Cholangiocarcinoma

2020 · Javier Vaquero, Florian Judée, et al. · Cancers · 73

PDF

Extracellular Vesicles in Hepatobiliary Malignancies

2018 · Ainhoa Lapitz, Ander Arbelaiz, et al. · Frontiers in Immunology · 68

PDF

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

2014 · Aura D Urribarri, Patricia Munoz-Garrido, et al. · Gut · 59

MicroRNAs and extracellular vesicles in cholangiopathies

2017 · P. Olaizola, P.Y. Lee-Law, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 50

PDF

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

2018 · David Fernández-Ramos, Pablo Fernández-Tussy, et al. · Cell Death and Disease · 47

PDF

Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

2017 · A. Arbelaiz, M. Azkargorta, et al. · Journal of Hepatology · 34

Zinc Finger E‐Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor–Stroma Paracrine Signaling

2021 · Cindy Lobe, Marie Vallette, et al. · Hepatology · 33

PDF

Genetic alterations shaping tumor response to anti-EGFR therapies

2022 · Javier Vaquero, Allan Pavy, et al. · Drug Resistance Updates · 25

Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

2020 · Alvaro Santos‐Laso, Laura Izquierdo‐Sanchez, et al. · Liver International · 25

Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy

2015 · Oihane Erice, Maite Merino-Azpitarte, et al. · Current Drug Targets · 8

Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma

2018 · Jesús Banales, M. Iñarrairaegui, et al. · Journal of Hepatology · 5

Proteomic Profiling of Extracellular Vesicles in Inflammatory Bowel Diseases

2025 · Montse Baldán-Martín, Mikel Azkargorta, et al. · International Journal of Molecular Sciences · 4

PDF

Intrinsic cancer cell phosphoinositide 3‐kinase δ regulates fibrosis and vascular development in cholangiocarcinoma

2023 · Vanessa Bou Malham, Nassima Benzoubir, et al. · Liver International · 3

PDF

Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients

2015 · Maria Chaparro, Iván Guerra, et al. · Gastroenterology · 2

Loss of Aquaporin-1 in Tumor Cells Fosters Intrahepatic Cholangiocarcinoma Progression

2025 · César I. Gaspari, Carine Beaupere, et al. · American Journal Of Pathology · 1

SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis

2019 · Jesús María Banales, Mercedes Iñarrairaegui, et al. · Journal of Hepatology · 1

Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)

2018 · A. Arbelaiz, A. Lapitz, et al. · Journal of Hepatology · 1

Overexpression of Mirna-506 in Human Cholangiocytes Causes Primary Biliary Cholangitis-Like Features including Mitochondrial Dysfunction and Increased Sensitivity to Apoptosis

2016 · O. Erice, P. Munoz-Garrido, et al. · Journal of Hepatology · 1

Works count: 42

Citation count: 1,505

H-index: 16

I10-index: 16